Interpace Biosciences Statistics
Total Valuation
Interpace Biosciences has a market cap or net worth of 11.66 million. The enterprise value is 63.27 million.
| Market Cap | 11.66M |
| Enterprise Value | 63.27M |
Important Dates
The next estimated earnings date is Friday, March 7, 2025.
| Earnings Date | Mar 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Interpace Biosciences has 4.40 million shares outstanding. The number of shares has increased by 2.28% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 4.40M |
| Shares Change (YoY) | +2.28% |
| Shares Change (QoQ) | +0.50% |
| Owned by Insiders (%) | 23.60% |
| Owned by Institutions (%) | 3.27% |
| Float | 3.36M |
Valuation Ratios
The trailing PE ratio is 2.39.
| PE Ratio | 2.39 |
| Forward PE | n/a |
| PS Ratio | 0.26 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 3.14 |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 8.60, with an EV/FCF ratio of 17.04.
| EV / Earnings | 13.46 |
| EV / Sales | 1.41 |
| EV / EBITDA | 8.60 |
| EV / EBIT | 9.95 |
| EV / FCF | 17.04 |
Financial Position
The company has a current ratio of 0.59
| Current Ratio | 0.59 |
| Quick Ratio | 0.50 |
| Debt / Equity | n/a |
| Debt / EBITDA | 0.98 |
| Debt / FCF | 1.93 |
| Interest Coverage | 8.13 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 28.09% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | 415,676 |
| Profits Per Employee | 43,519 |
| Employee Count | 108 |
| Asset Turnover | 3.17 |
| Inventory Turnover | 15.35 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +229.55% in the last 52 weeks. The beta is 0.67, so Interpace Biosciences's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | +229.55% |
| 50-Day Moving Average | 2.82 |
| 200-Day Moving Average | 1.80 |
| Relative Strength Index (RSI) | 53.18 |
| Average Volume (20 Days) | 7,875 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, Interpace Biosciences had revenue of 44.89 million and earned 4.70 million in profits. Earnings per share was 1.07.
| Revenue | 44.89M |
| Gross Profit | 27.14M |
| Operating Income | 6.36M |
| Pretax Income | 4.90M |
| Net Income | 4.70M |
| EBITDA | 6.63M |
| EBIT | 6.36M |
| Earnings Per Share (EPS) | 1.07 |
Balance Sheet
The company has 2.11 million in cash and 7.18 million in debt, giving a net cash position of -5.07 million or -1.15 per share.
| Cash & Cash Equivalents | 2.11M |
| Total Debt | 7.18M |
| Net Cash | -5.07M |
| Net Cash Per Share | -1.15 |
| Equity (Book Value) | -11.15M |
| Book Value Per Share | -13.10 |
| Working Capital | -7.66M |
Cash Flow
In the last 12 months, operating cash flow was 4.60 million and capital expenditures -889,000, giving a free cash flow of 3.71 million.
| Operating Cash Flow | 4.60M |
| Capital Expenditures | -889,000 |
| Free Cash Flow | 3.71M |
| FCF Per Share | 0.84 |
Margins
Gross margin is 60.46%, with operating and profit margins of 14.16% and 10.47%.
| Gross Margin | 60.46% |
| Operating Margin | 14.16% |
| Pretax Margin | 10.92% |
| Profit Margin | 10.47% |
| EBITDA Margin | 14.78% |
| EBIT Margin | 14.16% |
| FCF Margin | 8.27% |
Dividends & Yields
Interpace Biosciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.28% |
| Shareholder Yield | -2.28% |
| Earnings Yield | 40.24% |
| FCF Yield | 31.84% |
Stock Splits
The last stock split was on January 15, 2020. It was a reverse split with a ratio of 0.1.
| Last Split Date | Jan 15, 2020 |
| Split Type | Reverse |
| Split Ratio | 0.1 |
Scores
Interpace Biosciences has an Altman Z-Score of -20.21. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -20.21 |
| Piotroski F-Score | n/a |